Abstract: |
An antisense oligodeoxynucleotide directed against the 5′-untranslated region of MOR-1 blocks the analgesic actions of the μ1 analgesics morphine and [d-Ala2,d-Leu5jenkephalin (DADL) when they are microinjected into the periaqueductal gray. In contrast, morphine-6β-glucuronide (M6G) analgesia is unaffected by this treatment. Antisense oligodeoxynucleotides directed against distinct Giα subunits also distinguish between morphine and M6G analgesia. A probe targeting Giα2 blocks morphine analgesia, as previously reported, but is inactive against M6G analgesia. Conversely, an antisense oligodeoxynucleotide against GiαI inhibits M6G analgesia without affecting morphine analgesia. The antisense oligodeoxynucleotide directed against G0α is ineffective against both compounds. These results confirm the prior association of Giα2 with morphine analgesia and strongly suggests that M6G acts through a different opioid receptor, as revealed by its insensitivity towards the MOR-1 antisense probe and differential sensitivity towards G-protein α subunit antisense oligodeoxynucleotides. © 1995. |
Keywords: |
controlled study; unclassified drug; nonhuman; animal; animal tissue; animal experiment; gtp-binding proteins; molecular sequence data; rat; base sequence; rats; protein subunit; rats, sprague-dawley; morphine; analgesics, opioid; analgesics; guanine nucleotide binding protein; analgesia; mu opiate receptor; receptors, opioid, mu; receptor binding; tail flick test; naloxone; microinjections; oligonucleotides, antisense; enkephalin, ala(2)-mephe(4)-gly(5)-; antisense oligodeoxynucleotide; enkephalin[2 dextro alanine 4 methylphenylalanine 5 glycine]; periaqueductal gray matter; periaqueductal gray; narcotic antagonists; morphine derivatives; male; priority journal; article; enkephalin, leucine-2-alanine; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; enkephalins; enkephalin[2 dextro alanine 5 dextro leucine]; morphine-6β-glucuronide; morphine glucuronide
|